Atle Fund Management AB
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), Atle Fund Management AB reported 36 stock positions worth $212.8 million. Its top holding was Eli Lilly (LLY) at 12.7% of the portfolio, followed by Unitedhealth (UNH, 9.8%) and Merck (MRK, 8.3%). Compared with Q2 2024, it opened 3 new positions, sold out of 5, added to 28 and reduced 1. The biggest buy was Harmony Biosciences (HRMY, shares +335%) and the biggest sale an exit from Iqvia (IQV).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $212.8M (Q3 2024)
- SEC Filing
- 0001381843-24-000008 ↗ filed Nov 12, 2024
Holdings Value
Holdings 36 stocks · $212.8M
| LLY Eli Lilly & Co. | 12.73% | 30,564 | $27.1M | Add +12.6% |
| UNH Unitedhealth Group Inc. | 9.75% | 35,490 | $20.8M | Add +12.0% |
| MRK Merck & Co. Inc. | 8.26% | 154,699 | $17.6M | Add +37.2% |
| TMO Thermo Fisher Scientific Inc. | 6.40% | 22,012 | $13.6M | Add +13.1% |
| AMGN Amgen Inc. | 4.39% | 28,965 | $9.3M | Add +5.0% |
| BSX Boston Scientific Corp. | 4.18% | 106,172 | $8.9M | Reduce -0.4% |
| ABBV Abbvie Inc. | 4.13% | 44,486 | $8.8M | Add +24.9% |
| SYK Stryker Corp. | 3.98% | 23,460 | $8.5M | Add +17.4% |
| COR Cencora Inc. | 3.87% | 36,544 | $8.2M | Add +20.5% |
| VRTX Vertex Pharmaceuticals Inc. | 3.71% | 16,993 | $7.9M | Add +12.6% |
| REGN Regeneron Pharmaceuticals | 3.47% | 7,028 | $7.4M | Add +2.0% |
| NBIX Neurocrine Biosciences Inc. | 3.28% | 60,607 | $7.0M | Add +156.5% |
| ALKS Alkermes PLC | 3.11% | 236,610 | $6.6M | Add +243.9% |
| ITCI Intra-Cellular Therapies Inc. | 2.91% | 84,578 | $6.2M | Add +136.0% |
| HRMY Harmony Biosciences Holdings | 2.86% | 151,875 | $6.1M | Add +335.2% |
| UFPT Ufp Technologies Inc. | 2.69% | 18,048 | $5.7M | Add +84.2% |
| MIRM Mirum Pharmaceuticals Inc. | 2.54% | 138,321 | $5.4M | Add +83.9% |
| DXCM Dexcom Inc. | 1.69% | 53,757 | $3.6M | Add +55.9% |
| ACLX Arcellx Inc. | 1.58% | 40,230 | $3.4M | Add +78.8% |
| IONS Ionis Pharmaceuticals Inc. | 1.56% | 82,691 | $3.3M | Add +103.2% |
| CAH Cardinal Health Inc. | 1.43% | 27,500 | $3.0M | No change |
| FOLD Amicus Therapeutics Inc. | 1.38% | 275,472 | $2.9M | Add +85.9% |
| MRUS Merus NV | 1.19% | 50,687 | $2.5M | Add +64.4% |
| EW Edwards Lifesciences Corp. | 1.13% | 36,505 | $2.4M | No change |
| NAMS Newamsterdam Pharma Co. NV | 1.08% | 138,983 | $2.3M | Add +83.4% |
| SMMT Summit Therapeutics Inc. | 0.89% | 86,013 | $1.9M | New |
| IMCR Immunocore Holdings PLC-ADR | 0.79% | 54,060 | $1.7M | Add +127.3% |
| KRYS Krystal Biotech Inc. | 0.79% | 9,202 | $1.7M | Add +20.7% |
| AUTL Autolus Therapeutics PLC | 0.75% | 442,423 | $1.6M | Add +95.6% |
| CRBP Corbus Pharmaceuticals Holdi | 0.67% | 69,573 | $1.4M | Add +77.9% |
| BBIO Bridgebio Pharma Inc. | 0.64% | 53,432 | $1.4M | No change |
| SLNO Soleno Therapeutics Inc. | 0.63% | 26,390 | $1.3M | New |
| MERSANA THERAPEUTICS INC | 0.48% | 538,621 | $1.0M | Add +191.3% |
| MREO Mereo Biopharma Group PL-ADR | 0.39% | 200,000 | $822K | New |
| CABA Cabaletta Bio Inc. | 0.37% | 168,522 | $795K | Add +162.0% |
| PHVS Pharvaris NV | 0.30% | 34,328 | $636K | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| HRMY Harmony Biosciences Holdings | Add +335.2% | 2.86% | +2.21 |
| ALKS Alkermes PLC | Add +243.9% | 3.11% | +2.10 |
| ITCI Intra-Cellular Therapies Inc. | Add +136.0% | 2.91% | +1.41 |
| NBIX Neurocrine Biosciences Inc. | Add +156.5% | 3.28% | +1.30 |
| UFPT Ufp Technologies Inc. | Add +84.2% | 2.69% | +1.11 |
| MIRM Mirum Pharmaceuticals Inc. | Add +83.9% | 2.54% | +0.97 |
| SMMT Summit Therapeutics Inc. | New | 0.89% | +0.89 |
| ACLX Arcellx Inc. | Add +78.8% | 1.58% | +0.82 |
| SLNO Soleno Therapeutics Inc. | New | 0.63% | +0.63 |
| FOLD Amicus Therapeutics Inc. | Add +85.9% | 1.38% | +0.49 |
| ABBV Abbvie Inc. | Add +24.9% | 4.13% | +0.40 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.39% | +0.39 |
| IONS Ionis Pharmaceuticals Inc. | Add +103.2% | 1.56% | +0.37 |
| IMCR Immunocore Holdings PLC-ADR | Add +127.3% | 0.79% | +0.30 |
| AUTL Autolus Therapeutics PLC | Add +95.6% | 0.75% | +0.28 |
| MERSANA THERAPEUTICS INC | Add +191.3% | 0.48% | +0.25 |
| NAMS Newamsterdam Pharma Co. NV | Add +83.4% | 1.08% | +0.20 |
| CABA Cabaletta Bio Inc. | Add +162.0% | 0.37% | +0.08 |
| MRUS Merus NV | Add +64.4% | 1.19% | +0.08 |
| KRYS Krystal Biotech Inc. | Add +20.7% | 0.79% | −0.07 |
| UNH Unitedhealth Group Inc. | Add +12.0% | 9.75% | −0.08 |
| TMO Thermo Fisher Scientific Inc. | Add +13.1% | 6.40% | −0.16 |
| SYK Stryker Corp. | Add +17.4% | 3.98% | −0.16 |
| MRK Merck & Co. Inc. | Add +37.2% | 8.26% | −0.25 |
| COR Cencora Inc. | Add +20.5% | 3.87% | −0.30 |
| CRBP Corbus Pharmaceuticals Holdi | Add +77.9% | 0.67% | −0.40 |
| VRTX Vertex Pharmaceuticals Inc. | Add +12.6% | 3.71% | −0.60 |
| DXCM Dexcom Inc. | Add +55.9% | 1.69% | −0.69 |
| AMGN Amgen Inc. | Add +5.0% | 4.39% | −0.87 |
| REGN Regeneron Pharmaceuticals | Add +2.0% | 3.47% | −0.94 |
| LLY Eli Lilly & Co. | Add +12.6% | 12.73% | −2.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |